Ypsomed

Burgdorf, Switzerland Founded: 2001 • Age: 25 yrs Acquired By Techmed
Self-injection systems and diabetes care products are developed and manufactured.
Annual revenue $849.8M Latest available
Total funding $7.4M 1 rounds
Employees 2640 Tracked headcount
Investors 2 Known backers
Products 3 Services tracked
Competitors 10 Brand Intelligence

About Ypsomed

Ypsomed is a company based in Burgdorf (Switzerland) founded in 2001 was acquired by Techmed in April 2025. Ypsomed has raised $7.45 million across 1 funding round from investors including BV Partners and TecMed Deutschland. The company has 2,640 employees as of March 31, 2024. Ypsomed offers products and services including Ypsomed Delivery Systems, Ypsomed Diabetescare, and YpsoPump. Ypsomed operates in a competitive market with competitors including Tandem Diabetes, Insulet, Valeritas, Kaleido and CeQur, among others.

  • Headquarter Burgdorf, Switzerland
  • Employees 2640 as on 31 Mar, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Ypsomed Holding Ag
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $849.76 M (USD)
    36.54
    as on Mar 31, 2025
  • Net Profit
    $99.29 M (USD)
    11.66
    as on Mar 31, 2025
  • EBITDA
    $241.6 M (USD)
    36.55
    as on Mar 31, 2025
  • Total Equity Funding
    $7.45 M (USD)

    in 1 rounds

  • Latest Funding Round
    $7.45 M (USD), Series A

    Jun 01, 2003

  • Investors
    BV Partners

    & 1 more

  • Employee Count
    2640

    as on Mar 31, 2024

  • Acquired by
    Techmed

    (Apr 24, 2025)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Ypsomed

Ypsomed is a publicly listed company on the SIX with ticker symbol YPSN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: SIX · Ticker: YPSN · Sector: Health technology · Switzerland

Products & Services of Ypsomed

Ypsomed offers a comprehensive portfolio of products and services, including Ypsomed Delivery Systems, Ypsomed Diabetescare, and YpsoPump.

Product name locked
Category locked
Primary

Technologies for reliable self-medication injection devices.

Product name locked
Category locked
Locked

Products for easy diabetes self-treatment and monitoring.

Product name locked
Category locked
Locked

Simple insulin pump system for diabetes management.

People of Ypsomed

Headcount 1000-5000
Employee Profiles 139
Board Members and Advisors 4
Employee Profiles
People
Frank Mengis
COO
People
Olga Matveeva
Strategy And Business Development Lead
People
Nina Schefer
International Product Manager Infusion & AID
People
Nathalie da Eira
Market Intelligence And Strategy Team Lead, Diabetes Care

Unlock access to complete

Board Members and Advisors
people
Paul Fonteyne
Board Member
people
Martin Münchbach
Board Member
people
Gilbert Achermann
Chairman
people
Betül Susamis Unaran
Director

Unlock access to complete

Funding Insights of Ypsomed

Ypsomed has successfully raised a total of $7.45M through 1 strategic funding round. The most recent funding activity was a Series A round of $7.45 million completed in June 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Ypsomed

Ypsomed has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include BV Partners and TecMed Deutschland.

All
Venture Fund
Investor Description Founded Year Domain Location
Equity financing is offered by BV Partners for businesses.
Locked Locked Locked
TecMed Deutschland GmbH is focused on producing insulin pump components.
Locked Locked Locked
Premium access

Investor details for Ypsomed

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Ypsomed

Investments
Premium access

Investment portfolio details for Ypsomed

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Ypsomed

Premium access

Detailed financials for Ypsomed

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ypsomed Comparisons

Ypsomed Primary company
Description
Self-injection systems and diabetes care products are develo...
Location
Burgdorf, Switzerland
Founded Year
2001
Annual Revenue
$849.76 M (USD)
Net Profit
$99.29 M (USD)
EBITDA
$241.6 M (USD)
Employees
2,640
As of 2024
Premium access

Peer comparison for Ypsomed

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Ypsomed

Ypsomed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tandem Diabetes, Insulet, Valeritas, Kaleido and CeQur, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of devices for continuous glucose monitoring and manual insulin delivery
Locked Locked Locked
Wearable insulin infusion systems are developed for diabetes patients.
Locked Locked Locked
Wearable insulin patch pumps are developed for transdermal delivery.
Locked Locked Locked
Insulin pumps and monitoring software for diabetes are developed.
Locked Locked Locked
Wearable insulin delivery patches are developed for mealtime dosing.
Premium access

Detailed competitors of Ypsomed

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ypsomed

Premium access

Complete news archive for Ypsomed

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ypsomed

Ypsomed was founded in 2001 and raised its 1st funding round 2 years after it was founded.

Ypsomed is headquartered in Burgdorf, Switzerland. It is registered at Burgdorf, Bern, Switzerland.

Ypsomed is a funded company, having raised a total of $7.45M across 1 funding round to date.

As of Mar 31, 2024, the latest employee count at Ypsomed is 2,640.

Annual revenue of Ypsomed is $849.76M as on Mar 31, 2025.

Ypsomed was founded in 2001 in Burgdorf, Switzerland, where injection systems for self-medication and diabetes care products are developed and manufactured. The portfolio encompasses blood glucose monitoring systems, pen needles, safety devices, and infusion systems. Operations focus on the medical device sector, supplying tools for diabetes management and self-administration across global markets.

Ypsomed's top competitors include Tandem Diabetes, Insulet and Kaleido.

Ypsomed offers Ypsomed Delivery Systems, Ypsomed Diabetescare, and YpsoPump.

Yes, Ypsomed is publicly traded on SIX under the ticker symbol YPSN.

Ypsomed has 2 investors. Key investors include BV Partners, and TecMed Deutschland.

The ticker symbol of Ypsomed is YPSN on SIX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available